1. |
赵宇, 郭惠琴. NSCLC个体化治疗研究进展[J].癌症进展, 2011, 9(5):550-554.
|
2. |
张秀亮, 王颖, 刘刚, 等.晚期非小细胞肺癌四种化疗方案的最小成本分析[J].肿瘤学杂志, 2015, 21(8):645-650.
|
3. |
唐丹.晚期非小细胞肺癌化疗疗效的临床观察[J].四川医学, 2015, 36(10):1446-1448.
|
4. |
王杰, 胡学宁, 陈大兴.血清肿瘤标志物对晚期NSCLC放疗疗效的评估价值[J].实用癌症杂志, 2014, 29(6):626-628.
|
5. |
彭宇, 李峥, 熊艳丽, 等.晚期非小细胞肺癌不同含铂两药方案一线化疗预后因素的分析[J].第三军医大学学报, 2014, 36(16):1703-1708.
|
6. |
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
|
7. |
Ozkan Y, Yardim-Akaydin S, Firat HA, et al. Usefulness of homocysteine as a cancer marker:total thiol compounds and folate levels in untreated lung cancer patients[J]. Anticancer Res, 2007, 27(2):1185-1189.
|
8. |
Kohaar I, Kumar J, Thakur N, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population[J]. Biomarkers, 2010, 15(1):61-68.
|
9. |
于秀艳, 王文龙, 吴雪峰, 刘晓峰.非小细胞肺癌患者血清叶酸、同型半胱氨酸和维生素B_(12)的检测及其临床意义[J].吉林大学学报:医学版, 2015, 41(6):1235-1238.
|
10. |
Hanagiri T, Sugaya M, Takenaka M, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stageⅠnon-small cell lung cancer[J]. Lung Cancer, 2011, 74(1):112-117.
|
11. |
Cedrés S, Nuñez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3):172-179.
|
12. |
李军, 杨梅, 黄锦蓉.血清HCY、CYFRA21-1和CEA在晚期NSCLC患者化疗疗效评估中的临床应用[J].现代检验医学杂志, 2014, 29(1):147-149.
|
13. |
夏红安, 刘颖, 鲁小龙.晚期非小细胞肺癌患者化疗过程中监测外周血清同型半胱胺酸水平的临床意义[J].国际检验医学杂志, 2015, 36(16):2408-2409, 2411.
|
14. |
魏凯, 黄毅超.血浆同型半胱氨酸、叶酸和维生素B12水平与非小细胞肺癌的关系[J].国际检验医学杂志, 2012, 33(6):699, 701.
|
15. |
Baltar VT, Xun WW, Johansson M, et al. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk[J]. Eur J Epidemiol, 2013, 28(8):677-688.
|
16. |
Cui LH, Yu Z, Zhang TT, et al. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC[J]. Pharmacogenomics, 2011, 12(6):797-808.
|